An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

Asthma is a common prevalent chronic respiratory illness that affects millions of people all over the world in every age group. Asthma is defined as inflamed and constricted airways, causing repeated ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

Coughing and wheezing can leave anyone wondering whether it is asthma or bronchitis at play. Both of these respiratory issues ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. This week’s issue of the prestigious medical journal the Lancet is ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

asthma, lungs Authors review changes in the diagnosis, workup, and treatment of asthma in the 2022 GINA report. Some patients with asthma who lack evidence of type 2 inflammation are considered to ...